Summary of Research: Efficacy and Safety of the SGLT2 Inhibitor Empagliflozin Versus Placebo and the DPP-4 Inhibitor Linagliptin Versus Placebo in Young People with Type 2 Diabetes (DINAMO): A Multicentre, Randomised, Double-Blind, Parallel Group, Phase 3 Trial
AbstractThe increasing occurrence of childhood overweight and obesity has been followed by a substantial increase in youth-onset type 2 diabetes (T2D). Pharmacological treatment options for youth-onset T2D remain limited, with a clear unmet need for additional oral agents. This summary of research reports on the efficacy and safety of empagliflozin and linagliptin on glycaemic control in children and adolescents aged 10 –17 years with T2D in the randomised, double-blind, parallel group, phase 3 DINAMO trial. Empagliflozin provided a clinically relevant, statistically significant, and durable improvement in glycaemic con...
Source: Diabetes Therapy - April 5, 2024 Category: Endocrinology Source Type: research
SGLT2 Inhibitors – The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review
AbstractA substantial evidence base supports the use of sodium-glucose cotransporter-2 inhibitors (SGLT2is) in the treatment of type 2 diabetes mellitus (T2DM). This class of medicines has demonstrated important benefits that extend beyond glucose-lowering efficacy to protective mechanisms capable of slowing or preventing the onset of long-term cardiovascular, renal and metabolic (CVRM) complications, making their use highly applicable for organ protection and the maintenance of long-term health outcomes. SGLT2is have shown cost-effectiveness in T2DM management and economic savings over other glucose-lowering therapies due...
Source: Diabetes Therapy - April 5, 2024 Category: Endocrinology Source Type: research
Summary of Research: Efficacy and Safety of the SGLT2 Inhibitor Empagliflozin Versus Placebo and the DPP-4 Inhibitor Linagliptin Versus Placebo in Young People with Type 2 Diabetes (DINAMO): A Multicentre, Randomised, Double-Blind, Parallel Group, Phase 3 Trial
AbstractThe increasing occurrence of childhood overweight and obesity has been followed by a substantial increase in youth-onset type 2 diabetes (T2D). Pharmacological treatment options for youth-onset T2D remain limited, with a clear unmet need for additional oral agents. This summary of research reports on the efficacy and safety of empagliflozin and linagliptin on glycaemic control in children and adolescents aged 10 –17 years with T2D in the randomised, double-blind, parallel group, phase 3 DINAMO trial. Empagliflozin provided a clinically relevant, statistically significant, and durable improvement in glycaemic con...
Source: Diabetes Therapy - April 5, 2024 Category: Endocrinology Source Type: research
SGLT2 Inhibitors – The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review
AbstractA substantial evidence base supports the use of sodium-glucose cotransporter-2 inhibitors (SGLT2is) in the treatment of type 2 diabetes mellitus (T2DM). This class of medicines has demonstrated important benefits that extend beyond glucose-lowering efficacy to protective mechanisms capable of slowing or preventing the onset of long-term cardiovascular, renal and metabolic (CVRM) complications, making their use highly applicable for organ protection and the maintenance of long-term health outcomes. SGLT2is have shown cost-effectiveness in T2DM management and economic savings over other glucose-lowering therapies due...
Source: Diabetes Therapy - April 5, 2024 Category: Endocrinology Source Type: research
Canagliflozin inhibits PASMCs proliferation via regulating SGLT1/AMPK signaling and attenuates artery remodeling in MCT-induced pulmonary arterial hypertension
Biomed Pharmacother. 2024 Apr 3;174:116505. doi: 10.1016/j.biopha.2024.116505. Online ahead of print.ABSTRACTPulmonary arterial hypertension (PAH) was a devastating disease characterized by artery remodeling, ultimately resulting in right heart failure. The aim of this study was to investigate the effects of canagliflozin (CANA), a sodium-glucose cotransporter 2 inhibitor (SGLT2i) with mild SGLT1 inhibitory effects, on rats with PAH, as well as its direct impact on pulmonary arterial smooth muscle cells (PASMCs). PAH rats were induced by injection of monocrotaline (MCT) (40 mg/kg), followed by four weeks of treatment with ...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 4, 2024 Category: Drugs & Pharmacology Authors: Xiaojun Chen Xing Yu Guili Lian Huibin Tang Yan Yan Gufeng Gao Bangbang Huang Li Luo Liangdi Xie Source Type: research
Canagliflozin inhibits PASMCs proliferation via regulating SGLT1/AMPK signaling and attenuates artery remodeling in MCT-induced pulmonary arterial hypertension
Biomed Pharmacother. 2024 Apr 3;174:116505. doi: 10.1016/j.biopha.2024.116505. Online ahead of print.ABSTRACTPulmonary arterial hypertension (PAH) was a devastating disease characterized by artery remodeling, ultimately resulting in right heart failure. The aim of this study was to investigate the effects of canagliflozin (CANA), a sodium-glucose cotransporter 2 inhibitor (SGLT2i) with mild SGLT1 inhibitory effects, on rats with PAH, as well as its direct impact on pulmonary arterial smooth muscle cells (PASMCs). PAH rats were induced by injection of monocrotaline (MCT) (40 mg/kg), followed by four weeks of treatment with ...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 4, 2024 Category: Drugs & Pharmacology Authors: Xiaojun Chen Xing Yu Guili Lian Huibin Tang Yan Yan Gufeng Gao Bangbang Huang Li Luo Liangdi Xie Source Type: research
Effect of Luseogliflozin on Myocardial Flow Reserve in Patients with Type 2 Diabetes Mellitus (LUCENT-J Study)
AbstractIntroductionIn patients with type 2 diabetes (T2D), treatment with sodium –glucose cotransporter-2 (SGLT2) inhibitors has been shown to reduce hospital admission rates for heart failure (HF). However, the multiple mechanisms hypothesized and investigated to explain the cardioprotection of SGLT2 inhibitors are not fully understood.ObjectivesThe effect of luseogliflozin on myocardial flow reserve (MFR) in patients with T2D (LUCENT-J) study aims to examine the effects of SGLT2 inhibitors on myocardial perfusion.MethodsThe LUCENT-J study is a prospective, single-center, randomized, two-arm, parallel-group, open-label...
Source: Diabetes Therapy - April 4, 2024 Category: Endocrinology Source Type: research
Drug Therapy for Acute and Chronic Heart Failure with Preserved Ejection Fraction with Hypertension: A State-of-the-Art Review
AbstractIn this comprehensive state-of-the-art review, we provide an evidence-based analysis of current drug therapies for patients with heart failure with preserved ejection fraction (HFpEF) in the acute and chronic phases with concurrent hypertension. Additionally, we explore the latest developments and emerging evidence on the efficacy, safety, and clinical outcomes of common and novel drug treatments in the management of HFpEF with concurrent hypertension. During the acute phase of HFpEF, intravenous diuretics, mineralocorticoid receptor antagonists (MRAs), and vasodilators are pivotal, while in the chronic phase, angi...
Source: American Journal of Cardiovascular Drugs - April 4, 2024 Category: Cardiology Source Type: research
Effect of Luseogliflozin on Myocardial Flow Reserve in Patients with Type 2 Diabetes Mellitus (LUCENT-J Study)
AbstractIntroductionIn patients with type 2 diabetes (T2D), treatment with sodium –glucose cotransporter-2 (SGLT2) inhibitors has been shown to reduce hospital admission rates for heart failure (HF). However, the multiple mechanisms hypothesized and investigated to explain the cardioprotection of SGLT2 inhibitors are not fully understood.ObjectivesThe effect of luseogliflozin on myocardial flow reserve (MFR) in patients with T2D (LUCENT-J) study aims to examine the effects of SGLT2 inhibitors on myocardial perfusion.MethodsThe LUCENT-J study is a prospective, single-center, randomized, two-arm, parallel-group, open-label...
Source: Diabetes Therapy - April 4, 2024 Category: Endocrinology Source Type: research
Why have SGLT2 Inhibitors Failed to Achieve the Desired Success in COVID-19?
This article aims to uncover the reasons for the confusion in the literature and to unravel why SGLT2i failed to succeed in COVID-19 based on some solid evidence as well as speculative and personal perspectives.PMID:38566383 | DOI:10.2174/0113816128300162240322075423 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - April 3, 2024 Category: Drugs & Pharmacology Authors: Medine Cumhur Cure Erkan Cure Source Type: research
Why have SGLT2 Inhibitors Failed to Achieve the Desired Success in COVID-19?
This article aims to uncover the reasons for the confusion in the literature and to unravel why SGLT2i failed to succeed in COVID-19 based on some solid evidence as well as speculative and personal perspectives.PMID:38566383 | DOI:10.2174/0113816128300162240322075423 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - April 3, 2024 Category: Drugs & Pharmacology Authors: Medine Cumhur Cure Erkan Cure Source Type: research
Real-world evidence of the effects of sodium-glucose co-transporter 2 inhibitors on the dosing of diuretics in patients with heart failure: a retrospective cohort study
Conclusion: Treatment with SGLT2 inhibitors plus diuretic significantly reduced the patients’ diuretic requirements. Therefore, our finding supports the theoretical concept of minimizing the level of diuretic upon the initiation of SGLT2 inhibitors. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - April 2, 2024 Category: Drugs & Pharmacology Source Type: research
Comparative genomics incorporating translocation renal cell carcinoma mouse model reveals molecular mechanisms of tumorigenesis
Translocation renal cell carcinoma (tRCC) most commonly involves an ASPSCR1-TFE3 fusion, but molecular mechanisms remain elusive and animal models are lacking. Here, we show that human ASPSCR1-TFE3 driven by Pax8-Cre (a credentialed clear cell RCC driver) disrupted nephrogenesis and glomerular development, causing neonatal death, while the clear cell RCC failed driver, Sglt2-Cre, induced aggressive tRCC (as well as alveolar soft part sarcoma) with complete penetrance and short latency. However, in both contexts, ASPSCR1-TFE3 led to characteristic morphological cellular changes, loss of epithelial markers, and an epithelial...
Source: Journal of Clinical Investigation - April 1, 2024 Category: Biomedical Science Authors: Gopinath Prakasam, Akhilesh Mishra, Alana Christie, Jeffrey Miyata, Deyssy Carrillo, Vanina T. Tcheuyap, Hui Ye, Quyen N. Do, Yunguan Wang, Oscar Reig Torras, Ramesh Butti, Hua Zhong, Jeffrey Gagan, Kevin B. Jones, Thomas J. Carroll, Zora Modrusan, Steffe Source Type: research
Time to Benefit of SGLT-2 Inhibitors Among Patients with HF
Clinical question: What is the time to benefit for patients with heart failure (HF) and prescribed a sodium-glucose cotransporter-2 (SGLT-2) inhibitor?
Background: SGLT-2 inhibitors are an effective medication for patients with heart failure and preserved (HFpEF) or reduced ejection fraction (HRrEF).
Study design: Comparative effectiveness study
Setting: The authors conducted a systematic review of the literature up to the date of September 5, 2022. 636 articles were identified, and 449 papers were excluded due to meeting the exclusion criteria of a meta-analysis, review, nonhuman research study, correspondence, or editori...
Source: The Hospitalist - April 1, 2024 Category: Hospital Management Authors: Ronda Whitaker Tags: Cardiology In the Literature Source Type: research
SGLT2 Inhibitors and GLP-1 Agonists: A Beacon of Hope for Stroke Prevention in Diabetes
Diabetes Metab J. 2024 Mar;48(2):213-214. doi: 10.4093/dmj.2024.0079. Epub 2024 Mar 22.NO ABSTRACTPMID:38556704 | DOI:10.4093/dmj.2024.0079 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - April 1, 2024 Category: Endocrinology Authors: Jae-Han Jeon Source Type: research
